Open AccessEffects of shuxuetong injection for cerebral infarction
Author(s) -
Hua Fang,
Honglong Zhou,
Jicai Zhang,
Ziyi Li,
Zhen Chen,
Raorao Yuan,
Xiangqun Huang,
Junyong Yang,
Jianqiang Zhang,
Shuo Wang,
Yong Huang,
HU Shang-wei
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021929
Subject(s) - medicine , cochrane library , medline , randomized controlled trial , protocol (science) , meta analysis , medical physics , physical therapy , alternative medicine , pathology , political science , law
Background: Cerebral infarction (CI) is a common disease with high morbidity and disability. Shuxuetong (SXT) injection is a Chinese Materia Medica standardized product used in the treatment of CI. Currently, there is a lack of high-quality evidence to support the effectiveness and safety of SXT on patients with CI. This systematic review protocol aims at describing a meta-analysis to evaluate the efficacy of SXT for the treatment of CI. Methods: We will search the databases of PubMed, MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, China national knowledge infrastructure database (CNKI), Wan fang database, Chongqing VIP information, and SinoMed from their inception to Jun 2020. Two reviewers will independently screen Randomized controlled trials of SXT for the treatment of CI. The meta-analysis will be conducted using RevMan V.5.3 software. Results: The results of this study will be published in a peer-reviewed journal. Conclusion: The conclusion of our systematic review will provide evidence to judge whether SXT is an effective intervention for patients with CI. Trial registration number: 10.17605/OSF.IO/3F6ZH.